Surrozen to Present at Upcoming Healthcare Investor Conference

Rhea-AI Summary

Surrozen (Nasdaq: SRZN) announced that company management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026. The presentation will be a fireside chat at 11:30 AM Eastern Time / 8:30 AM Pacific Time.

A live audio webcast will be available via the Investors section of Surrozen’s website, with a replay archived on surrozen.com for at least 30 days.

News Market Reaction – SRZN

-1.70%

4 alerts

-1.70% Session close to close

$361.31M Market Cap

0.3x Rel. Volume

In the May 13 session, SRZN declined 1.70%, reflecting a mild negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Surrozen’s participation in the H.C. Wainwright BioConnect conference o...

Analysis

This announcement highlights Surrozen’s participation in the H.C. Wainwright BioConnect conference on May 19, 2026, offering a webcasted fireside chat at 11:30 AM ET and a replay for at least 30 days. It follows recent earnings updates and prior conference appearances that produced mixed price reactions. Investors may watch for any incremental commentary relative to past disclosures, including the Q1 2026 cash balance of $106.9M and the existing ATM prospectus detailed in the 424B5 filing.

Key Figures

ATM capacity: $50,000,000 Reference share price: $25.15 Illustrative ATM shares: 11,762,608 shares +5 more

8 metrics

ATM capacity $50,000,000 Prospectus supplement 424B5 ATM program with TD Securities (USA) LLC

Reference share price $25.15 Assumed price in ATM prospectus (last reported sale on March 20, 2026)

Illustrative ATM shares 11,762,608 shares Maximum shares if full $50,000,000 sold at $25.15 per share

ATM fee rate 3.0% Maximum compensation on gross proceeds to TD Cowen under Sales Agreement

Cash & equivalents $106.9M Balance as of March 31, 2026 from Q1 2026 results

Collaboration revenue $5.0M Boehringer Ingelheim milestone revenue recognized in Q1 2026

Conference time ET 11:30 AM H.C. Wainwright BioConnect fireside chat on May 19, 2026

Webcast archive period 30 days Replay availability on Surrozen website after conference presentation

Historical Context

5 past events · Latest: May 06 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 06	Earnings update	Neutral	-9.9%	Q1 2026 financial results and business update with milestone revenue.
Apr 28	Inducement grant	Neutral	+1.9%	Stock option grant of 2,020 shares to new non-executive employee.
Mar 23	Earnings update	Neutral	-0.9%	Fourth-quarter and full-year 2025 results with business update and milestone.
Feb 25	Conference presentation	Neutral	-4.7%	Announcement of TD Cowen healthcare conference fireside chat and webcast access.
Feb 23	Inducement grant	Neutral	+1.6%	Equity inducement option for 3,070 shares to newly hired employee.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news tagged as earnings or corporate updates often saw negative price moves, even when fundamentally neutral, with only inducement grants showing positive alignment.

Recent Company History

Over the last several months, Surrozen issued multiple earnings and corporate updates, including Q1 2026 results on May 06, 2026 and FY2025 results on March 23, 2026. It also reported several Nasdaq Rule 5635(c)(4) inducement grants and prior conference participation. Price reactions were mixed, with three events showing negative moves despite neutral updates and two inducement grants aligning with modest gains. Today’s conference announcement fits the pattern of routine investor-relations activity rather than a new fundamental catalyst.

Key Terms

at‑the‑market sales agreement, prospectus supplement, nasdaq listing rule 5635(c)(4), non-statutory stock option, +4 more

8 terms

at‑the‑market sales agreement financial

"offer up to $50,000,000 of common stock through an at‑the‑market sales agreement"

An at‑the‑market sales agreement lets a public company sell newly issued shares directly into the open market over time through a broker, at the current trading price rather than a fixed offering price. Investors care because it provides flexible, on‑demand funding but can increase the number of shares outstanding and put downward pressure on the stock price — like turning a faucet on and off instead of dumping a whole bucket at once.

prospectus supplement regulatory

"[424B5] Surrozen, Inc./DE Prospectus Supplement (Debt Securities)"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

nasdaq listing rule 5635(c)(4) regulatory

"inducement grant under Nasdaq Listing Rule 5635(c)(4) dated April 24, 2026"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-statutory stock option financial

"The company granted a non-statutory stock option for 2,020 shares"

A non-statutory stock option is a company-granted right that lets a person buy shares later at a set price but does not receive special tax-favored treatment under tax law. It matters to investors because when the option is used the holder usually pays ordinary income tax on the gain and the company records compensation cost and issues new shares, which can reduce existing owners’ percentage ownership—think of it like a coupon to buy stock that creates a taxable event and some dilution.

form 4 regulatory

"[Form 4] Surrozen, Inc./DE Insider Trading Activity"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

View in glossary

rule 16b-3(d) regulatory

"transaction exempt under Rule 16b-3(d) and Rule 16b-3(c)."

Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.

rule 16b-3(c) regulatory

"transaction exempt under Rule 16b-3(d) and Rule 16b-3(c)."

An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.

webcast technical

"Interested parties may access the live audio webcast for the conference"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.

H.C. Wainwright 4^th Annual BioConnect Investor Conference on Tuesday, May 19, 2026

Fireside Chat at 11:30 AM Eastern Time / 8:30 AM Pacific Time

Interested parties may access the live audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surrozen.com/events-presentations/events-calendar. A replay of the webcasts will be archived on the website at www.surrozen.com for at least 30 days.

About Surrozen 
Surrozen is a biotechnology company, pioneering a new class of Wnt-based therapeutics designed to harness the power of Wnt signaling to treat sight-threatening ophthalmic conditions. Built on deep scientific expertise and a proprietary antibody-engineering platform, Surrozen develops multifunctional biologics that selectively activate Wnt signaling in combination with other key disease pathways. Our approach aims to deliver best-in-class, durable therapies that have the potential to transform patient outcomes in some of the most pressing unmet medical needs in ocular diseases. For more information, visit www.surrozen.com. 

Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidates (including anticipated clinical development plans and timelines, the availability of data, the potential for such product candidates to be used to treat human disease or address unmet needs in serious eye diseases, as well as the potential benefits and potential differentiation from existing therapies of such product candidates); Surrozen’s intention to submit an IND application for SZN-8141 in 2026; and expectations regarding Surrozen’s partnership with Boehringer Ingelheim, including the potential for future success-based development, regulatory, and commercial milestone payments, in addition to mid-single digit to low-double digit royalties on sales. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to its product candidates and potential future drug candidates; the Company’s ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen’s ability to identify, develop and commercialize drug candidates; Surrozen’s ability to successfully complete preclinical and clinical studies for its product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen’s Annual Report on Form 10-K for the year ended December 31, 2025, and Surrozen’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk Factors,” and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Investor/Media Contact
Email: Investorinfo@surrozen.com

FAQ

When will Surrozen (SRZN) present at the H.C. Wainwright BioConnect Investor Conference in 2026?

Surrozen will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026. According to Surrozen, the session will be a scheduled fireside chat for investors and analysts.

What time is Surrozen’s (SRZN) fireside chat at the 2026 H.C. Wainwright BioConnect Conference?

Surrozen’s fireside chat is set for 11:30 AM Eastern Time / 8:30 AM Pacific Time. According to Surrozen, this session is part of the H.C. Wainwright 4th Annual BioConnect Investor Conference agenda.

How can investors listen to Surrozen’s (SRZN) presentation at the May 19, 2026 H.C. Wainwright conference?

Investors can access a live audio webcast via the Investors section of Surrozen’s website. According to Surrozen, the webcast link will be available under its events and presentations calendar.

Will a replay of Surrozen’s (SRZN) 2026 H.C. Wainwright BioConnect Conference webcast be available?

Yes, a replay of Surrozen’s conference webcast will be archived on surrozen.com for at least 30 days. According to Surrozen, investors can revisit the presentation after the live event.

Where on Surrozen’s (SRZN) website can I find the 2026 H.C. Wainwright conference webcast?

The webcast can be found in the Investors section of Surrozen’s website, under events and presentations. According to Surrozen, both the live audio and replay will be accessible from this section.